Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Keros Therapeutics Inc (NQ: KROS )

47.44 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 47.44
Bid (Size) 45.00 (3)
Ask (Size) 62.53 (1)
Prev. Close 47.44
Today's Range 47.44 - 47.44
52wk Range 27.02 - 73.00
Shares Outstanding 23,337,862
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target. 
Via Benzinga
KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024
KROS stock results show that Keros Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+9.99%
+9.99%
1 Month
-3.89%
-3.89%
3 Month
-17.75%
-17.75%
6 Month
-10.78%
-10.78%
1 Year
+12.95%
+12.95%

More News

Read More
Keros Therapeutics Inc. (NASDAQ: KROS) Near the Top of Equities by Percentage Gain on 1/4
Via Investor Brand Network
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Where Keros Therapeutics Stands With Analysts
Via Benzinga
Recap: Keros Therapeutics Q1 Earnings
Via Benzinga
Recap: Keros Therapeutics Q3 Earnings
Via Benzinga
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial
Via Benzinga
Keros Therapeutics Posts Encouraging Preclinical Data Of RKER-012 In Type Of High Blood Pressure
Via Benzinga
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
Via Benzinga
Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Shares of Keros Therapeutics Jumped This Week
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023
Via Benzinga
BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
Via Benzinga
Why Shares of Keros Therapeutics Rose 10.2% This Week
Via The Motley Fool
Alphatec Holdings, Immatics And Some Other Big Stocks Moving Higher On Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
76 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.